Loading...
Market
Story
BridgeBio Receives FDA Approval for Heart Disease Drug Attruby™ (acoramidis)
Nov 23, 2024, 12:12 AM
BridgeBio Pharma Inc. (BBIO) has received FDA approval for its drug Attruby™ (acoramidis), a near-complete TTR stabilizer (≥90%), to reduce cardiovascular death and hospitalization in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). The approval will trigger a $500 million payment to BridgeBio under its royalty funding agreement. BridgeBio will provide further details on the Attruby label and access programs in a management call on November 22, 2024, at 8:00 pm ET. The approval is seen as a significant milestone for the company, and the share price is expected to react positively.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved in the US only • 25%
Approved in the US and EU • 25%
Approved in the US, EU, and other regions • 25%
Not approved in any region • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
